Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCOMPLISH: Pembrolizumab plus lenvatinib in advanced adrenal cortical carcinoma
KCT0006789Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in adrenal cancer (ACC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jul 2022; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on KCT0006789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006789.